TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03633916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom sensitization session
Description: A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School-level sensitization activities
Description: The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-level sensitization activities
Description: The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~1. Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~2. A drop-box for student self-referral slips will be set up in a prominent location at each school.~3. Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial.
Study: NCT02494648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]
Description: CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT02538406

Intervention type: OTHER
Intervention: Segmental withdrawal
Description: Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
Study: NCT00501137

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV (Human Papillomavirus) Vaccine
Description: HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV (Human Papillomavirus) Vaccine
Description: HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV (Human Papillomavirus) Vaccine
Description: HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
Study: NCT00768287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IB1001
Description: Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: nonacog alfa
Description: Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
Study: NCT01357005

Intervention type: OTHER
Intervention: No intervention would be provided in this research
Description: No intervention would be provided in this research, but need to draw blood
Study: NCT02652702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: circular stapler-assisted colostomy
Description: procedure:circular stapler-assisted colostomy device:circular stapler

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional hand-stitching colostomy
Description: procedure:hand-stitching colostomy
Study: NCT03056014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: giving varying doses of NAC in order to determine which reduces oxidative stress.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl cysteine
Description: giving varying doses of NAC in order to determine which reduces oxidative stress.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 6 Fish oil ( PUFA)
Description: giving varying doses of PUFA in order to determine which reduces oxidative stress.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: omega 6 Fish oil ( PUFA)
Description: giving varying doses of PUFA in order to determine which reduces oxidative stress.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: L-alanine placebo pill to determine if effect is supplement related or random effect.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: L-alanine placebo pill to determine if effect is supplement related or random effect.
Study: NCT02710227

Intervention type: OTHER
Intervention: (PSQI), (STQ).
Description: Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).

Intervention type: OTHER
Intervention: (PSQI), (STQ).
Description: Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
Study: NCT03272906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Description: 2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: 2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-language therapy
Description: Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Speech-language therapy
Description: Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
Study: NCT03935256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Paclitaxel
Description: Regimen I: Carboplatin AUC 6 \& Paclitaxel 175mg/m2 given intravenously for 4 cycles during weeks 1, 10, 13, 16 Regimen II: Carboplatin AUC 2 \& Paclitaxel 45mg/m2 given intravenously for 2 cycles during weeks 4 \& 7 concurrent with radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: An external beam radiation dose of 45 Gy in 25 fractions is routinely prescribed to the Planning Target Volume (PTV) for postoperative radiotherapy.~The Vaginal Brachytherapy (VBT) Boost will be delivered after the external beam radiation. Doses of 12-18 Gy in 2-3 fractions are often prescribed to the surface of the vagina to a treatment length of 3-5 cm. There is no standard dose or fractionation schedule, so this dose, fractionation, location of dose specification , and length of vagina treated will be individualized for the patient and will be at the discretion of the treating radiation oncologist.
Study: NCT04315805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Yoga therapy will be based on personalised care consisting of Yoga relaxing posture, strengthening exercise, Yoga breathing, meditative psychotherapy, sound and imagery yoga practices, relaxation, yoga diet and life style management.
Study: NCT01592045

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch14.18 -NCI
Description: 25 mg/m\^2/day IV for four consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch14.18 -NCI
Description: 25 mg/m\^2/day IV for four consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch14.18-UTC
Description: 17.5 mg/m\^2/day IV for four consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ch14.18-UTC
Description: 17.5 mg/m\^2/day IV for four consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Description: GM-CSF will be administered SC at a dose of 250 mcg/m\^2/day for 14 days during Courses 1, 3, and 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Description: GM-CSF will be administered SC at a dose of 250 mcg/m\^2/day for 14 days during Courses 1, 3, and 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin (IL-2)
Description: Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m\^2/day for the first week and at a dose of 4.5 MIU/m\^2/day for the second week during Courses 2 and 4.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin (IL-2)
Description: Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m\^2/day for the first week and at a dose of 4.5 MIU/m\^2/day for the second week during Courses 2 and 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight \> 12 kg: 80 mg/m\^2/dose twice daily (total daily dose is 160 mg/m\^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight \> 12 kg: 80 mg/m\^2/dose twice daily (total daily dose is 160 mg/m\^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily).
Study: NCT01395004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: GSK2110183 was orally administered at 125 mg once daily.
Study: NCT04966026

Intervention type: OTHER
Intervention: No inervention
Description: No inervention
Study: NCT05457751

Intervention type: PROCEDURE
Intervention: Rocuronium injection pain
Description: 1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath

Intervention type: PROCEDURE
Intervention: Rocuronium injection pain
Description: 1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath

Intervention type: PROCEDURE
Intervention: Rocuronium injection pain
Description: 1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath

Intervention type: PROCEDURE
Intervention: Rocuronium injection pain
Description: 1: no reaction, 2: movement only in the ankle, 3: movement or withdrawal only in the arm (shoulder and ankle), 4: diffuse reaction (movement or withdrawal in more than one extremity, coughing and holding breath
Study: NCT04249570

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Study: NCT03728751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Paravertebral dry needling C7-T4. Total of 8 needles.
Study: NCT03510897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teprasiran
Description: IV injection
Study: NCT01415934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: discontinue statins
Description: patients will be randomized to either continue taking statins or discontinue.
Study: NCT03510897

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic saline
Study: NCT03916406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 06835919
Description: 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 06835919
Description: 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 7.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 7.5 mg
Study: NCT02579590

Intervention type: DRUG
Intervention: Depot Medroxyprogesterone Acetate 150 mg
Description: the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month

Intervention type: DRUG
Intervention: Implanon( 68 mg etonogestrel implant)
Description: where they are using etonogestrel 68 mg implant (Implanon; Organon)

Intervention type: DRUG
Intervention: Cerazette pills (75 micrograms desogestrel)
Description: where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
Study: NCT02570659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Video
Description: A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
Study: NCT04567381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Services
Description: In enhanced services, the provision of services go beyond just referring a patient and leaving them to follow-through on their own accord. ES varies based on resources, model of service delivery, philosophy, and role and responsibilities of team members. Enhanced services usually includes longer-term case management which can then facilitate the connection to clinical counseling, victim assistance, familial assistance, legal assistance, emergency financial funding, transportation for subsequent appointments related to a patient's medical condition, employment assistance, and assistance in educational program enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individuals randomized to TAU will receive a list of resources which provides participants with community agency information that they can engage on their own. The list of resources will include contact information for various services such as housing, employment, mental health and legal services. Patients randomized into this condition receive little to no assistance from program staff and must navigate the vast terrain of social service providers on their own.
Study: NCT02844452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
Study: NCT02792595

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Negative Control
Description: Untreated area

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control
Description: High SPF Standard P3/SPF 15

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product A
Description: Yosemite Falls (Forte Day SPF upgrade) Variant A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product B
Description: Yosemite Falls (Forte Day SPF upgrade) Variant B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product C
Description: Yosemite Falls (Forte Day SPF upgrade) Variant C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product D
Description: Yosemite Falls (Forte Day SPF upgrade) Variant D

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product E
Description: Yosemite Falls (Forte Day SPF upgrade) Variant E

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product F
Description: Yosemite Falls (Forte Day SPF upgrade) Variant F

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product G
Description: Yosemite Falls (Forte Day SPF upgrade) Variant G
Study: NCT00802321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
Study: NCT03056612

Intervention type: OTHER
Intervention: Observation protocol
Description: The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
Study: NCT02792595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Product H
Description: Yosemite Falls (Forte Day SPF upgrade) Variant H
Study: NCT03056612

Intervention type: OTHER
Intervention: Observation protocol
Description: The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.

Intervention type: OTHER
Intervention: Observation protocol
Description: The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
Study: NCT03457623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Innovative Supported
Description: addition of connected tools and stronger accompaniment to improve quality of life
Study: NCT03441100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMA202 Product
Description: The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
Study: NCT00977925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Pad
Description: Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
Study: NCT03922282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gasless BABA
Description: BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classic BABA
Description: BABA robotic-thyroidectomy that is using carbon dioxide.
Study: NCT02583412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero®
Description: Multicomponent meningococcal B vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bexsero®
Description: Multicomponent meningococcal B vaccine
Study: NCT00977925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
Study: NCT00929409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate tablets
Description: Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
Study: NCT03020121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy/biopsy
Description: Colposcopy/biopsy will be performed on all subjects
Study: NCT01897974

Intervention type: OTHER
Intervention: Survey
Description: Families complete survey to measure medication compliance.
Study: NCT02796235

Intervention type: OTHER
Group type: OTHER
Intervention: Venous Doppler ultrasound of the lower limbs
Description: Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
Study: NCT02583412

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: Hepatitis A vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix®
Description: Hepatitis A vaccine
Study: NCT06253910

Intervention type: OTHER
Group type: OTHER
Intervention: Patients selection
Description: Patient selection were selected according to selected criteria.

Intervention type: OTHER
Group type: OTHER
Intervention: Patients selection
Description: Patient selection were selected according to selected criteria.

Intervention type: OTHER
Group type: OTHER
Intervention: Recall visits
Description: Following the operations, periodontal measurements were measured at the baseline, third month, first and second years.